bwkhoo
2021-10-21
Is this consider a piece of good news for NVAX?
UPDATE 1-India's Serum sees 'large' exports as output nearly quadruples
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
1
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":853501532,"tweetId":"853501532","gmtCreate":1634821600479,"gmtModify":1634821601059,"author":{"id":3576444918223783,"idStr":"3576444918223783","authorId":3576444918223783,"authorIdStr":"3576444918223783","name":"bwkhoo","avatar":"https://static.tigerbbs.com/62d6e46769c7f3e2599cb62434f5f5c3","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":36,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Is this consider a piece of good news for NVAX? </p></body></html>","htmlText":"<html><head></head><body><p>Is this consider a piece of good news for NVAX? </p></body></html>","text":"Is this consider a piece of good news for NVAX?","highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/853501532","repostId":2177046847,"repostType":2,"repost":{"id":"2177046847","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1634819611,"share":"https://ttm.financial/m/news/2177046847?lang=&edition=full","pubTime":"2021-10-21 20:33","market":"us","language":"en","title":"UPDATE 1-India's Serum sees 'large' exports as output nearly quadruples","url":"https://stock-news.laohu8.com/highlight/detail?id=2177046847","media":"Reuters","summary":"(Adds details, quotes) By Krishna N. Das NEW DELHI, Oct 21 (Reuters) - The Serum Institute of In","content":"<html><body><p>(Adds details, quotes)</p><p> By Krishna N. Das</p><p> NEW DELHI, Oct 21 (Reuters) - The Serum Institute of India <a href=\"https://laohu8.com/S/SII\">$(SII)$</a>, the world's biggest vaccine maker, has nearly quadrupled its monthly capacity of AstraZeneca shots to as many as 240 million doses and is prepared to export \"large volumes\" from January, its CEO told Reuters.</p><p> India this month resumed COVID-19 vaccine exports for the first time since April, sending some 4 million doses to friendly countries but none yet to the global vaccine-sharing platform COVAX </p><p>SII's monthly production was around 65 million doses when the Indian government stopped all exports as the country's infections soared.</p><p> \"Because we have converted so many buildings and plants for it, 220-240 million is our output now - which is enough for the country,\" CEO Adar Poonawalla said after India celebrated the milestone of administering 1 billion doses </p><p>on Thursday.</p><p> \"India may need booster shots and other things also, so exports in January won't reach as high as 200 million doses. But certainly, it will be large volumes.\"</p><p> The family-owned company may be able to export up to 30 million doses a month in November and December, he added.</p><p> \"The government will decide how many doses we export, I think 20-30 million could happen in November - volumes will be small until December,\" Poonawalla said, adding he did not know yet if any exports to COVAX would happen in October. </p><p> SII is contracted to supply hundreds of millions of doses to WHO-backed COVAX but has supplied only a few dozen million shots. The company has provided nearly 90% of the doses administered in India.</p><p> Poonawalla also said SII would make only the single-dose Sputnik Light vaccine from Russia and not the two-dose Sputnik V. He said the output will mainly be exported.</p><p> SII could also produce 50 million to 100 million doses of the Novavax vaccine by December, Poonawalla said, again mainly for exports.</p><p> Novavax has sought regulatory approvals for the vaccine in India, Indonesia and the Philippines, and plans to do so in the United States this year. </p><p> \"COVID vaccine demand, with boosters, will sustain for a few years, but after two-three years it should hopefully go down,\" Poonawalla said.</p><p> (Reporting by Krishna N. Das, Editing by Timothy Heritage and Elaine Hardcastle)</p><p>((Krishna.Das@tr.com; ;))</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>UPDATE 1-India's Serum sees 'large' exports as output nearly quadruples</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUPDATE 1-India's Serum sees 'large' exports as output nearly quadruples\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-10-21 20:33</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>(Adds details, quotes)</p><p> By Krishna N. Das</p><p> NEW DELHI, Oct 21 (Reuters) - The Serum Institute of India <a href=\"https://laohu8.com/S/SII\">$(SII)$</a>, the world's biggest vaccine maker, has nearly quadrupled its monthly capacity of AstraZeneca shots to as many as 240 million doses and is prepared to export \"large volumes\" from January, its CEO told Reuters.</p><p> India this month resumed COVID-19 vaccine exports for the first time since April, sending some 4 million doses to friendly countries but none yet to the global vaccine-sharing platform COVAX </p><p>SII's monthly production was around 65 million doses when the Indian government stopped all exports as the country's infections soared.</p><p> \"Because we have converted so many buildings and plants for it, 220-240 million is our output now - which is enough for the country,\" CEO Adar Poonawalla said after India celebrated the milestone of administering 1 billion doses </p><p>on Thursday.</p><p> \"India may need booster shots and other things also, so exports in January won't reach as high as 200 million doses. But certainly, it will be large volumes.\"</p><p> The family-owned company may be able to export up to 30 million doses a month in November and December, he added.</p><p> \"The government will decide how many doses we export, I think 20-30 million could happen in November - volumes will be small until December,\" Poonawalla said, adding he did not know yet if any exports to COVAX would happen in October. </p><p> SII is contracted to supply hundreds of millions of doses to WHO-backed COVAX but has supplied only a few dozen million shots. The company has provided nearly 90% of the doses administered in India.</p><p> Poonawalla also said SII would make only the single-dose Sputnik Light vaccine from Russia and not the two-dose Sputnik V. He said the output will mainly be exported.</p><p> SII could also produce 50 million to 100 million doses of the Novavax vaccine by December, Poonawalla said, again mainly for exports.</p><p> Novavax has sought regulatory approvals for the vaccine in India, Indonesia and the Philippines, and plans to do so in the United States this year. </p><p> \"COVID vaccine demand, with boosters, will sustain for a few years, but after two-three years it should hopefully go down,\" Poonawalla said.</p><p> (Reporting by Krishna N. Das, Editing by Timothy Heritage and Elaine Hardcastle)</p><p>((Krishna.Das@tr.com; ;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"http://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2177046847","content_text":"(Adds details, quotes) By Krishna N. Das NEW DELHI, Oct 21 (Reuters) - The Serum Institute of India $(SII)$, the world's biggest vaccine maker, has nearly quadrupled its monthly capacity of AstraZeneca shots to as many as 240 million doses and is prepared to export \"large volumes\" from January, its CEO told Reuters. India this month resumed COVID-19 vaccine exports for the first time since April, sending some 4 million doses to friendly countries but none yet to the global vaccine-sharing platform COVAX SII's monthly production was around 65 million doses when the Indian government stopped all exports as the country's infections soared. \"Because we have converted so many buildings and plants for it, 220-240 million is our output now - which is enough for the country,\" CEO Adar Poonawalla said after India celebrated the milestone of administering 1 billion doses on Thursday. \"India may need booster shots and other things also, so exports in January won't reach as high as 200 million doses. But certainly, it will be large volumes.\" The family-owned company may be able to export up to 30 million doses a month in November and December, he added. \"The government will decide how many doses we export, I think 20-30 million could happen in November - volumes will be small until December,\" Poonawalla said, adding he did not know yet if any exports to COVAX would happen in October. SII is contracted to supply hundreds of millions of doses to WHO-backed COVAX but has supplied only a few dozen million shots. The company has provided nearly 90% of the doses administered in India. Poonawalla also said SII would make only the single-dose Sputnik Light vaccine from Russia and not the two-dose Sputnik V. He said the output will mainly be exported. SII could also produce 50 million to 100 million doses of the Novavax vaccine by December, Poonawalla said, again mainly for exports. Novavax has sought regulatory approvals for the vaccine in India, Indonesia and the Philippines, and plans to do so in the United States this year. \"COVID vaccine demand, with boosters, will sustain for a few years, but after two-three years it should hopefully go down,\" Poonawalla said. (Reporting by Krishna N. Das, Editing by Timothy Heritage and Elaine Hardcastle)((Krishna.Das@tr.com; ;))","news_type":1,"symbols_score_info":{"NVAX":0.9}},"isVote":1,"tweetType":1,"viewCount":616,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":38,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/853501532"}
精彩评论